Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Attempts to develop MET-targeted therapies have historically focused on MET-expressing
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …

Background A splice-site mutation that results in a loss of transcription of exon 14 in the
oncogenic driver MET occurs in 3 to 4% of patients with non–small-cell lung cancer …

Introduction KRAS mutations have been recognized as undruggable for many years.
Recently, novel KRAS G12C inhibitors, such as sotorasib and adagrasib, are being …

Purpose: Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors
(TKI) are poorly understood. We aimed to characterize the genomic mechanisms of …

Lung cancer is the leading cause of cancer death worldwide. In the past decade EGFR, ALK
and ROS1 TKIs lead to an unprecedented survival improvement of oncogene-addicted …

In the United States, lung cancer is the second most frequently diagnosed type of cancer
and the leading cause of cancer deaths. 1 Non–small-cell lung cancer (NSCLC), which …

Targeted therapies have revolutionized the treatment and improved the outcome for
oncogene-driven NSCLC and an increasing number of oncogenic driver therapies have …

Aberrant MET signaling can drive tumorigenesis in several cancer types through a variety of
molecular mechanisms including MET gene amplification, mutation, rearrangement, and …

The high morbidity and mortality of non-small cell lung cancer (NSCLC) have always been
major threats to people's health. With the identification of carcinogenic drivers in non-small …